Mangoceuticals, Inc.

Overview

Mangoceuticals, Inc. is a Texas-based company that operates a telehealth platform and sells branded compounded wellness products through a related-party pharmacy. The company went public in March 2023 and trades on the Nasdaq Capital Market under the ticker MGRX.

Core business model

• Platform: MangoRx connects consumers with licensed healthcare professionals via a telehealth portal (MangoRX.com). Prescribed products are fulfilled through a licensed pharmacy.
• Product scope: Focus on men’s wellness via telemedicine and a line of compounded products, plus an oral testosterone replacement therapy (TRT) product sold as PRIME (Powered by Kyzatrex®).
• Revenue model: Revenue is generated from customer purchases of pharmaceutical and compounded products sold through the MangoRx platform. Subscription options are offered where applicable.

Primary products and brands

• Compounded products (MangoRx brand):
  • Mango ED: rapid-dissolve sublingual tablets for erectile dysfunction containing Sildenafil or Tadalafil, Oxytocin, and L-Arginine.
  • Mango GROW: rapid-dissolve chewables for hair growth with Minoxidil, Finasteride, Vitamin D3, and Biotin.
  • SLIM: rapid-dissolve chewables for weight management containing Vitamin B6 and Semaglutide.
  • MOJO: chewable hormone balance tablet with DHEA, Pregnenolone, and Enclomiphene Citrate.
• PRIME: oral TRT product branded as PRIME, powered by Kyzatrex®, delivered in a softgel capsule designed for lymphatic absorption.
• Regulatory note: Compounded products are not FDA-approved and are produced under Section 503A exemptions; they are compounded per individual prescription and ingredients are publicly disclosed.

Telehealth and fulfillment structure

• Telemedicine providers: Contracted providers (LocumTele, Locum Tenens USA) supply physicians who perform telehealth consultations and determine prescription eligibility.
• Related-party pharmacy: Epiq Scripts, LLC, which is currently 52% owned by CEO Jacob Cohen, compounds and fulfills prescribed products and provides services under a Master Services Agreement and related SOW.
• Channel flow: Patient request via Mangoceuticals platform → telehealth consultation by contracted physicians → prescription to Epiq Scripts → compounding, fulfillment, and shipping to patient → revenue to Mangoceuticals.
• Regulatory and compliance considerations: State-level corporate practice of medicine and fee-splitting restrictions affect ongoing compliance. Epiq Scripts holds licenses in DC and 49 states (Alabama licensure targeted by mid-2026).

Partnerships, licenses, and product expansions

• Marketing and branding: Marketing arrangements for Kyzatrex® TRT with Marius Pharmaceuticals, LLC.
• Master distribution and license agreements:
  • ISFLST: Master Distribution Agreement covering GROW and ED products for Asia Pacific and Latin America, with potential exclusive rights in certain markets.
  • Propre Energie Inc.: Master Distribution Agreement for Dermytol® (skin hyperpigmentation/brightening) including share and revenue-sharing provisions.
• Patent-related acquisitions:
  • Intramont Technologies: patents related to infection prevention; 10% royalty to Mangoceuticals on gross worldwide sales using the patents; grant-back license and ROFR on future patent sales.
  • Greenfield Investments: mushroom-derived patents; 10% royalty to Mangoceuticals; grant-back license and ROFR on future patent sales.
• Product rollout: Dermytol, a plant-based dermatology line, is planned for marketing beginning in Q2 2026.
• Other agreements: Arrangements with PrevenTech (respiratory illness technology) and Cubes Operations (digital asset treasury services) include longer-term commercial or treasury-management provisions.

Digital assets and treasury strategy (MULTI-DAT)

• MangoDAT, LLC intends to deploy up to $100 million in a Solana-focused digital asset treasury (DAT) with Cube Operations LLC, using MPC wallets to store, manage, and transact Solana. The plan targets staking yields in the 7–8% range and focuses on liquidity management.
• The company has used a MULTI-DAT branding strategy and has contemplated capital markets offerings to fund treasury initiatives.

Corporate structure and control

• Parent-subsidiary contribution (Dec 2024): Mango & Peaches Corp. acquired key assets (MangoRx Mexico and MangoRx UK) from Mangoceuticals and issued Mangoceuticals 4,999,999 shares of Mango & Peaches common stock. Mango & Peaches assumed related liabilities.
• Voting and control: Mango & Peaches authorized 100 shares of Series A Super Majority Voting Preferred Stock. Design features give Jacob D. Cohen controlling voting rights in Mango & Peaches through class vote mechanisms and Series A voting power. Cohen holds meaningful economic and voting influence.
• Equity dynamics: Common stock issued to Cohen and the design of preferred stock create potential pathways for future dilution and shifts in control through additional issuances or equity actions.

Financial highlights

• Net income (loss):
  • 2025: Net loss of $20,643,455
  • 2024: Net loss of $8,707,226
• Accumulated deficit:
  • 2025: $40,647,480
  • 2024: $20,004,486
• Public company status and listing:
  • Nasdaq-listed under ticker MGRX.
  • Received a Nasdaq non-compliance notice for minimum bid price as of February 4, 2026. A 1-for-15 reverse stock split was implemented in October 2024 to address a prior deficiency. The company faces delisting risk if price and listing standards are not restored.

Headcount and staffing

• Leadership: CEO and Chairman Jacob D. Cohen; CFO Eugene Johnston.
• The company uses independent contractors for administrative and technology development work.

Customer and market focus

• Primary market focus on erectile dysfunction (ED), hair loss, testosterone/hormone balance therapies, and weight management, with market studies and competitive context cited for those categories.

One-line summary

Mangoceuticals operates a telehealth platform for men’s wellness paired with compounded, prescription-based products fulfilled by a related-party pharmacy, while pursuing TRT marketing, international distribution and licensing agreements, and a digital-asset treasury strategy; recent financials show ongoing losses and a growing accumulated deficit.